Brexit: Pharmacovigilance Requirements for UK MAHs

Following the Brexit, the MHRA posted an updated guidance to become familiar with the pharmacovigilance requirements for UK marketing authorization holders (MAHs).

MHRA´s guidance on UK pharmacovigilance requirements  

In the blog post, the agency provides sources of guidance and further information, including the following:

  • In general, the EU Good Pharmacovigilance Practices (GVP, EudraLex Volume 9) continues to apply in the UK.
  • There are some exceptions and modifications to the EU GVP that apply to UK MAHs and the MHRA.
  • Guidance on the submission of the summary of pharmacovigilance system details and on the UK QPPV and the pharmacovigilance system master file (PSMF).
  • Guidance on Pharmacovigilance procedures (e.g. submission of adverse drug reactions reports and PSURs).
  • Frequently asked questions (available by contacting the respective pharmaceutical trade association via Email).

For more information please read the post Guidance on pharmacovigilance requirements for UK authorized products from 1 January 2021 on the MHRA blog.

Go back


Stay informed with the GMP Newsletters from ECA

GMP Newsletter

The ECA offers various free of charge GMP newsletters for which you can subscribe to according to your needs.

To subscribe, please click here.